Office Action Predictor
Last updated: April 16, 2026
Application No. 18/185,876

HEMOLYSIS-REDUCTION CONNECTOR FOR DIRECT BLOOD DRAW

Final Rejection §102§112
Filed
Mar 17, 2023
Examiner
CERIONI, DANIEL LEE
Art Unit
3791
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Carefusion 303, INC.
OA Round
2 (Final)
65%
Grant Probability
Moderate
3-4
OA Rounds
3y 6m
To Grant
87%
With Interview

Examiner Intelligence

Grants 65% of resolved cases
65%
Career Allow Rate
485 granted / 749 resolved
-5.2% vs TC avg
Strong +22% interview lift
Without
With
+21.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
81 currently pending
Career history
830
Total Applications
across all art units

Statute-Specific Performance

§101
9.3%
-30.7% vs TC avg
§103
40.4%
+0.4% vs TC avg
§102
17.6%
-22.4% vs TC avg
§112
30.4%
-9.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 749 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Notice of Amendment In response to the amendment(s) filed on 1/9/26, amended claim(s) 1, 4, 12, and 16-17, canceled claim(s) 2 and 13, and new claim(s) 18-19 is/are acknowledged. The following new and/or reiterated ground(s) of rejection is/are set forth: Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim(s) 12 and 14-18 is/are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. For claim 12, the claim terms “an extension” (line 8) and “an extension” (line 9) are ambiguous. It is unclear whether the same extensions are being referred to or whether these are supposed to be different extensions. The claim is examined under the former interpretation. Dependent claim(s) 14-18 fail to cure the ambiguity of independent claim 12, thus claim(s) 12 and 14-18 is/are rejected under 35 U.S.C. 112(b). Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1, 3-6, 12, and 14-19 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by U.S. Patent Application Publication No. 2021/0228127 to Burkholz et al. (hereinafter “Burkholz”). For claim 1, Burkholz discloses a flow restriction device (55) (Figs. 6A and 6C) (para [0055]), comprising: a male luer connector portion (60 including 14 and 50) (as can be seen in Figs. 6A-C) (para [0053] and [0056]) comprising an inner surface (unlabeled, but as can be seen in Figs. 6B-C) defining a first cavity (unlabeled, but as can be seen in Figs. 6A-C) and a first lumen in fluid-flow continuity with the first cavity (unlabeled, but as can be seen in Figs. 6A-C); and a female luer connector portion (58 including 16 and 18) (as can be seen in Figs. 6A-C) (para [0056] and [0059]) comprising an extension (structure identified by reference numeral “58” in Fig. 6C) (para [0056]) and an inner surface (unlabeled, but as can be seen in Figs. 6B-C) defining a second cavity along the extension (the negative space inside the structure identified by reference numeral “58” in Fig. 6C that connects 62 to the lumen that is adjacent to 63) and a second lumen (unlabeled, but the lumen that is adjacent to element 63 Fig. 6C) in fluid-flow continuity with the second cavity (unlabeled, but as can be seen in Figs. 6A-C) (para [0056] and [0060]), the extension comprising: a first end (unlabeled, but as can be seen in Figs. 6A-C); a second end (unlabeled, but as can be seen in Figs. 6A-C); an outer surface (unlabeled, but as can be seen in Figs. 6A-C); and a channel (56) (Figs. 6A and 6C) (para [0056]) defined on the outer surface of the extension (as can be seen in Figs. 6A and 6C) (para [0056]), wherein the channel is helically disposed around the outer surface of the extension and extends between the first and second ends (as can be seen in Figs. 6A and 6C) (para [0056]), the extension is configured to be at least partially disposed within the first cavity (as can be seen in Figs. 6A and 6C), and the channel and an inner surface of the male luer connector portion define a fluid passage in fluid-flow continuity with the first lumen, the second cavity, and the second lumen (as can be seen in Figs. 6A and 6C) (para [0056]). For claim 3, Burkholz further discloses wherein the channel is in fluid-flow continuity with the second lumen via a port (62) (Fig. 6A) extending through the extension (para [0060]) (see more generally para [0056]-[0060]). For claim 4, Burkholz further discloses wherein the fluid passage is configured to increase flow resistance through the fluid passage to reduce shear stress experienced by the fluid (as can be seen in Fig. 6A) (para [0034]-[0035]). For claim 5, Burkholz further discloses wherein the first lumen is configured to be coupled to a catheter hub (“catheter hub,” para [0029]-[0030]). For claim 6, Burkholz further discloses wherein the second lumen is configured to be coupled to a fluid collection device (34) (Fig. 2) (para [0045]). For claim 12, Burkholz discloses a peripheral intravenous catheter assembly (“peripheral intravenous catheter,” para [0029]-[0030]) configured to limit hemolysis during drawing of blood from a patient (Abstract) (para [0034]-[0035]), comprising: a catheter hub having a proximal end and a distal end (“catheter hub,” para [0029]-[0030]); a fluid collection device (34) (Fig. 2) (para [0045]); and a flow restriction device (55) (Figs. 6A and 6C) (para [0055]), comprising: a male luer connector portion (60 including 14 and 50) (as can be seen in Figs. 6A-C) (para [0053] and [0056]) comprising an inner surface (unlabeled, but as can be seen in Figs. 6B-C) defining a first cavity (unlabeled, but as can be seen in Figs. 6A-C) and a first lumen in fluid-flow continuity with the first cavity and the catheter hub (unlabeled, but as can be seen in Figs. 6A-C); and a female luer connector portion (58 including 16 and 18) (as can be seen in Figs. 6A-C) (para [0056] and [0059]) comprising an extension (structure identified by reference numeral “58” in Fig. 6C) (para [0056]) and an inner surface (unlabeled, but as can be seen in Figs. 6B-C) defining a second cavity along the extension (the negative space inside the structure identified by reference numeral “58” in Fig. 6C that connects 62 to the lumen that is adjacent to 63) and a second lumen (unlabeled, but the lumen that is adjacent to element 63 Fig. 6C) in fluid-flow continuity with the fluid collection device (as can be seen in Figs. 6A-C) and an extension in fluid-flow continuity wit the second cavity (unlabeled, but as can be seen in Figs. 6A-C) (para [0056] and [0060]), the extension comprising: a first end (unlabeled, but as can be seen in Figs. 6A-C); a second end (unlabeled, but as can be seen in Figs. 6A-C); an outer surface (unlabeled, but as can be seen in Figs. 6A-C); and a channel (56) (Figs. 6A and 6C) (para [0056]) defined on the outer surface of the extension (as can be seen in Figs. 6A and 6C) (para [0056]), wherein the channel is helically disposed around the outer surface of the extension and extends between the first and second ends (as can be seen in Figs. 6A and 6C) (para [0056]), the extension is configured to be at least partially disposed within the first cavity (as can be seen in Figs. 6A and 6C), and the channel and an inner surface of the male luer connector portion define a fluid passage in fluid-flow continuity with the first lumen, the second cavity, and the second lumen (as can be seen in Figs. 6A and 6C) (para [0056]). For claim 14, Burkholz further discloses wherein the channel is in fluid-flow continuity with the second lumen via a port (62) (Fig. 6A) extending through the extension (para [0060]) (see more generally para [0056]-[0060]). For claim 15, Burkholz further discloses wherein the fluid passage is configured to increase flow resistance through the fluid passage to reduce shear stress experienced by the fluid (as can be seen in Fig. 6A) (para [0034]-[0035]). For claim 16, Burkholz further discloses wherein the first lumen is configured to be coupled to the catheter hub (“catheter hub,” para [0029]-[0030]). For claim 17, Burkholz further discloses wherein the second lumen is configured to be coupled to the fluid collection device (34) (Fig. 2) (para [0045]). For claim 18, Burkholz further discloses wherein the extension comprises a port (62) (Fig. 6A) forming a fluid path between the channel and the second cavity (para [0056] and [0060])). For claim 19, Burkholz further discloses wherein the extension comprises a port (62) (Fig. 6A) forming a fluid path between the channel and the second cavity (para [0056] and [0060])). Response to Arguments Applicant’s arguments filed 1/9/26 have been fully considered. With respect to the claim objection, Applicant’s amendments and arguments are persuasive and thus claim objection is withdrawn. With respect to the 112(b) rejections, Applicant’s amendments and arguments are persuasive and thus the rejections are withdrawn. With respect to the 102 rejections, Applicant’s arguments have been considered but are moot because the arguments do not address the new grounds of rejection necessitated by Applicant’s amendments presented in the response filed 1/9/26. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DANIEL LEE CERIONI whose telephone number is (313) 446-4818. The examiner can normally be reached M - F 8:00 AM - 5:00 PM PT. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer Robertson can be reached at (571) 272-5001. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DANIEL L CERIONI/Primary Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

Mar 17, 2023
Application Filed
Oct 17, 2025
Non-Final Rejection — §102, §112
Jan 09, 2026
Response Filed
Jan 26, 2026
Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599338
DEFLECTABLE ELONGATED GUIDEWIRE ASSEMBLY
2y 5m to grant Granted Apr 14, 2026
Patent 12601641
Temperature Estimation Method, Temperature Estimation Program and Temperature Estimation Device
2y 5m to grant Granted Apr 14, 2026
Patent 12594062
FLUID COLLECTION ASSEMBLIES INCLUDING AN EXTENSION
2y 5m to grant Granted Apr 07, 2026
Patent 12588949
LASER ABLATION WITH ELECTROMAGNETIC ENERGY FEEDBACK
2y 5m to grant Granted Mar 31, 2026
Patent 12582344
WIRELESS STIMULATION PROBE DEVICE FOR WIRELESS NERVE INTEGRITY MONITORING SYSTEMS
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
65%
Grant Probability
87%
With Interview (+21.8%)
3y 6m
Median Time to Grant
Moderate
PTA Risk
Based on 749 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in for Full Analysis

Enter your email to receive a magic link. No password needed.

Free tier: 3 strategy analyses per month